ALung is now proud to be part of LivaNova.

The HEMOLUNG is specifically designed to remove up to 50% of metabolically produced CO2 which can minimize the harms associated with mechanical ventilation.


The HEMOLUNG can be used to prevent intubation and invasive mechanical ventilation when non-invasive ventilation is failing. The HEMOLUNG can enable rapid patient stabilization by reducing work of breathing and correcting hypercapnia and respiratory acidosis.

Acute and Chronic on Ventilator

The HEMOLUNG can enable application of lung protective ventilation strategies to reduce the risks of ventilator-induced lung injury.

HEMOLUNG Registry Analysis

The HEMOLUNG Registry program collects de-identified patient data to analyze the real-world use of the HEMOLUNG. An analysis of 176 Registry patients was performed to demonstrate the physiologic benefits and safety of HEMOLUNG therapy as a tool to correct pH and PaCO2 in patients with acute respiratory failure.

Hypercapnia and respiratory acidosis in ventilated patients is a known predictor of increased mortality, hospital and ICU lengths of stay, organ dysfunction and ventilator complications.1-2 

Intubation following NIV failure in COPD patients is associated with increased mortality compared to patients treated with NIV alone (27% vs 9%).3

All reported adverse events were expected complications of extracorporeal blood circulation, including bleeding, thrombosis and hemolysis. Specific design of the HEMOLUNG for low-blood flow extracorporeal CO2 removal reduces the risks of extracorporeal lung support.


HEMOLUNG Difference
HEMOLUNG Publications

Indication for Use: The HEMOLUNG is indicated for respiratory support that provides extracorporeal carbon dioxide (CO2) removal from the patient’s blood for up to 5 days in adults with acute, reversible respiratory failure for whom ventilation of CO2 cannot be adequately or safely achieved using other available treatment options and continued clinical deterioration is expected.

  1. Nin N, Muriel A, Peñuelas O, et al. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. Intensive Care Med. 2017;43(2):200-208.
  2. Tiruvoipati R, Pilcher D, Buscher H, Botha J, Bailey M. Effects of Hypercapnia and Hypercapnic Acidosis on Hospital Mortality in Mechanically Ventilated Patients*: Critical Care Medicine. 2017;45(7):e649-e656.
  3. Chandra D, Stamm JA, Taylor B, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med. 2012;185(2):152-159.